Literature DB >> 11139438

The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways.

D T Schmidt1, N Watson, G Dent, E Rühlmann, D Branscheid, H Magnussen, K F Rabe.   

Abstract

Non-selective inhibitors of cyclic nucleotide phosphodiesterase (PDE) block allergen-induced contraction of passively sensitized human airways in vitro by a dual mechanism involving a direct relaxant effect on smooth muscle and inhibition of histamine and cysteinyl leukotriene (LT) release from airways. We investigated the effects of non-selective PDE inhibitors and selective inhibitors of PDE3 and PDE4 in order to determine the involvement of PDE isoenzymes in the suppression of allergic bronchoconstriction. Macroscopically normal airways from 76 patients were sensitized with IgE-rich sera (>250 u ml(-1)) containing specific antibodies against allergen (Dermatophagoides farinae). Contractile responses of bronchial rings were assessed using standard organ bath techniques. Passive sensitization caused increased contractile responses to allergen, histamine and LTC(4). Non-selective PDE inhibitors (theophylline, 3-isobutyl-1-methylxanthine [IBMX]), a PDE3-selective inhibitor (motapizone), PDE4-selective inhibitors (RP73401, rolipram, AWD 12-281) and a mixed PDE3/4 inhibitor (zardaverine) all significantly relaxed inherent bronchial tone at resting tension and to a similar degree. Theophylline, IBMX, zardaverine and the combination of motapizone and RP73401 inhibited the contractile responses to allergen and LTC(4). Pre-treatment with motapizone, RP73401, rolipram or the methylxanthine adenosine receptor antagonist, 8-phenyltheophylline, did not significantly decrease responses to either allergen or LTC(4). We conclude that combined inhibition of PDE3 and PDE4, but not selective inhibition of either isoenzyme or antagonism of adenosine receptors, is effective in suppressing allergen-induced contractions of passively sensitized human airways. The relationship between allergen- and LTC(4)-induced responses suggests that PDE inhibitors with PDE3 and PDE4 selectivity are likely to act in part through inhibition of mediator release and not simply through direct relaxant actions on airway smooth muscle.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11139438      PMCID: PMC1572487          DOI: 10.1038/sj.bjp.0703725

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  46 in total

1.  Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients.

Authors:  S Myou; M Fujimura; Y Kamio; Y Ishiura; H Tachibana; T Hirose; T Hashimoto; T Matsuda
Journal:  Am J Respir Crit Care Med       Date:  1999-09       Impact factor: 21.405

2.  Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase.

Authors:  S H Soderling; S J Bayuga; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

Review 3.  Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors.

Authors:  K H Banner; C P Page
Journal:  Clin Exp Allergy       Date:  1996-03       Impact factor: 5.018

4.  Characterization of inflammatory mediator release from purified human lung mast cells.

Authors:  R P Schleimer; D W MacGlashan; S P Peters; R N Pinckard; N F Adkinson; L M Lichtenstein
Journal:  Am Rev Respir Dis       Date:  1986-04

5.  Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A.

Authors:  S H Soderling; S J Bayuga; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

Review 6.  Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic.

Authors:  T J Torphy; M S Barnette; D C Underwood; D E Griswold; S B Christensen; R D Murdoch; R B Nieman; C H Compton
Journal:  Pulm Pharmacol Ther       Date:  1999       Impact factor: 3.410

7.  Passive sensitization of human airways increases responsiveness to leukotriene C4.

Authors:  D Schmidt; E Ruehlmann; D Branscheid; H Magnussen; K F Rabe
Journal:  Eur Respir J       Date:  1999-08       Impact factor: 16.671

8.  The effect of theophylline and enprofylline on allergen-induced bronchoconstriction.

Authors:  R Pauwels; D Van Renterghem; M Van der Straeten; N Johannesson; C G Persson
Journal:  J Allergy Clin Immunol       Date:  1985-10       Impact factor: 10.793

9.  Arachidonic acid metabolism in purified human lung mast cells.

Authors:  S P Peters; D W MacGlashan; E S Schulman; R P Schleimer; E C Hayes; J Rokach; N F Adkinson; L M Lichtenstein
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

10.  Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro.

Authors:  K D Cooper; K Kang; S C Chan; J M Hanifin
Journal:  J Invest Dermatol       Date:  1985-06       Impact factor: 8.551

View more
  21 in total

1.  Transforming Growth Factor-β1 Decreases β2-Agonist-induced Relaxation in Human Airway Smooth Muscle.

Authors:  Christie A Ojiaku; Elena Chung; Vishal Parikh; Jazmean K Williams; Anthony Schwab; Ana Lucia Fuentes; Maia L Corpuz; Victoria Lui; Sam Paek; Natalia M Bexiga; Shreya Narayan; Francisco J Nunez; Kwangmi Ahn; Rennolds S Ostrom; Steven S An; Reynold A Panettieri
Journal:  Am J Respir Cell Mol Biol       Date:  2019-08       Impact factor: 6.914

2.  Contractile responses to adenosine, R-PIA and ovalbumen in passively sensitized guinea-pig isolated airways.

Authors:  Timothy J Martin; Kenneth J Broadley
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

3.  Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility.

Authors:  R Venkatasamy; D Spina
Journal:  Br J Pharmacol       Date:  2016-07-07       Impact factor: 8.739

4.  Chronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors.

Authors:  John A Meyers; Derrick W Su; Adam Lerner
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

Review 5.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 6.  Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.

Authors:  Katharine H Banner; Neil J Press
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

Review 7.  Using guinea pigs in studies relevant to asthma and COPD.

Authors:  Brendan J Canning; Yangling Chou
Journal:  Pulm Pharmacol Ther       Date:  2008-02-02       Impact factor: 3.410

8.  Identification of a potent new chemotype for the selective inhibition of PDE4.

Authors:  Amanda P Skoumbourdis; Ruili Huang; Noel Southall; William Leister; Vicky Guo; Ming-Hsuang Cho; James Inglese; Marshall Nirenberg; Christopher P Austin; Menghang Xia; Craig J Thomas
Journal:  Bioorg Med Chem Lett       Date:  2008-01-11       Impact factor: 2.823

Review 9.  PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast.

Authors:  Victoria Boswell-Smith; Domenico Spina
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

Review 10.  Evaluation of PDE4 inhibition for COPD.

Authors:  Desuo Wang; Xiangli Cui
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.